Bulk Pharmaceutical API Sources for pentoxifylline

Bulk Pharmaceutical API Sources for pentoxifylline

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jbuI`@DXtX@dyEEEEDbddUFRLyjjZjZfX@@
ASINEX		BAS 00897429
Calbiochem		516354

Bulk Active Pharmaceutical Ingredient (API) Sources for Pentoxifylline

Last updated: February 20, 2026

Pentoxifylline is a phosphodiesterase inhibitor used to improve blood flow in peripheral vascular disease and other circulatory disorders. The supply chain for its active pharmaceutical ingredient (API) is distributed among several key regions and manufacturers.

Major API Producers and Geographic Distribution

Leading Countries in API Manufacturing

• China: Supplies approximately 60-70% of global pentoxifylline API. Major manufacturers include Zhejiang Hisun Pharmaceutical Co., Ltd. and others licensed under international standards.

• India: Accounts for roughly 20-25% of global supply. Noted companies include Mylan, Sun Pharmaceutical Industries Ltd., and Lupin.

• European Union and United States: The remaining 5-15% involves specialty and generic API producers with high-quality standards, often for branded formulations.

Key Manufacturers and Suppliers

Region	Notable Companies	Production Capacity	Certification & Standards
China	Zhejiang Hisun, Guangzhou Pharm. Factory	Large-scale	GMP, ISO 9001
India	Mylan, Sun Pharma, Lupin	Moderate to large	EU GMP, US FDA, ISO 9001
Europe/US	Evonik Industries, Imports via CDMOs	Smaller scale	EU GMP, US FDA

API Quality and Regulatory Status

• Most Chinese and Indian manufacturers produce APIs conforming to Good Manufacturing Practice (GMP) standards, with many holding certifications from the US FDA, EMA, or local authorities.

• Suppliers in developed regions tend to have higher regulatory oversight, providing APIs suitable for regulated markets.

Supply Chain Dynamics

Market Entry Barriers

• Regulatory Compliance: Strict GMP standards are mandatory for APIs supplied to markets like the US and EU, limiting entry for smaller suppliers.

• Pricing: Chinese API producers benefit from lower production costs, leading to competitive pricing but with ongoing scrutiny regarding quality assurance.

• Patent Status: Pentoxifylline's patent protections expired decades ago, enabling multiple generic manufacturers to produce APIs, increasing supply diversity.

Recent Supply Trends

• COVID-19 Pandemic: Disruptions caused delays in Chinese API exports due to factory shutdowns and increased global demand for quality APIs.

• Regulatory Tightening: USFDA and EMA audits have prompted some Indian and Chinese manufacturers to upgrade manufacturing processes, briefly impacting supply availability.

Quality Considerations

• Manufacturers adhering to US FDA and EMA standards are preferred for brands requiring high-regulatory compliance.

• Non-compliant sources risk quality issues, which can affect drug safety and efficacy, prompting rigorous supplier qualification processes.

Summary of API Sources for Pentoxifylline

Region	Main Companies	Estimated Market Share	Regulatory Certifications
China	Zhejiang Hisun, Guangzhou Pharm.	60-70%	GMP, ISO 9001, China Food & Drug Administration
India	Mylan, Sun Pharma, Lupin	20-25%	US FDA, EU GMP, ISO 9001
Europe/US	Evonik Industries, US-based CDMOs	5-15%	US FDA, EMA, ISO 9001

---

Key Takeaways

• China remains the dominant API source for pentoxifylline, characterized by extensive capacity and competitive prices.

• Indian manufacturers supply a significant share, with increasing quality standards aligned with Western regulatory agencies.

• Regulatory compliance is essential for APIs used in branded and generic pharmaceuticals for markets like US and EU.

• Supply chain disruptions are possible due to geopolitical and regulatory factors, impacting lead times and pricing.

• Quality assurance and certification status influence procurement decisions, especially in regulated markets.

FAQs

1. What factors influence the choice of API supplier for pentoxifylline?
Regulatory compliance, manufacturing capacity, quality standards (GMP certification), price, and supply reliability are primary considerations.

2. Are there risks associated with sourcing APIs from China or India?
Yes. Variability in manufacturing practices and regulatory oversight can pose quality and supply risks. Qualified supplier audits mitigate this.

3. How do certification standards impact API quality?
Certifications like US FDA, EMA, and ISO 9001 affirm adherence to quality, safety, and manufacturing practices, ensuring API consistency and regulatory acceptance.

4. Is pentoxifylline API supply stable?
Generally, yes, but recent supply chain disruptions linked to global events have caused fluctuations. Multiple sources increase supply stability.

5. What developments could affect future API sourcing?
Emerging regulations, trade policies, and manufacturing upgrades in China and India could influence supply availability, cost, and regulatory approval processes.

---

References

[1] European Medicines Agency. (2021). API manufacturing standards. EMA Website.

[2] U.S. Food and Drug Administration. (2020). Guidance for API suppliers. FDA.

[3] Marketline. (2022). Global Active Pharmaceutical Ingredient Market Report.

[4] GlobalData. (2021). API Supply Chain Dynamics in the Americas and Asia.

[5] IQVIA. (2022). Global API Manufacturing Trends.